References
- Vertex Pharmaceuticals . Vertex and obsidian therapeutics establish collaboration to discover novel therapies that regulate gene editing (2021). https://news.vrtx.com/press-release/vertex-and-obsidian-therapeutics-establish-collaboration-discover-novel-therapies
- BusinessWire . Biotech EryPharm announces a revolutionary technological breakthrough in the large- scale manufacturing of red blood cells (2021). www.businesswire.com/news/home/20210408005145/en/Biotech-EryPharm-Announces-a-Revolutionary-Technological-Breakthrough-in-the-Large--Scale-Manufacturing-of-Red-Blood-Cells
- Giarratana MC , KobariL , LapillonneHet al. Ex vivo generation of fully mature human red blood cells from hematopoietic stem cells. Nat. Biotechnol.23, 69–74 (2005).
- Agenus . Agenus doses first cancer patient with iNKT cell therapy. (2021) https://investor.agenusbio.com/node/17801/pdf
- IMV . IMV announces company-sponsored clinical trial in patients with r/rDLBCL in collaboration with Merck following feedback from FDA (2021). www.imv-inc.com/news-events/press-releases/detail/679/imv-announces-company-sponsored-clinical-trial-in-patients
- Tessa Therapeutics . Tessa therapeutics announces enrollment of 12 patient pilot cohort in its relapsed or refractory hodgkin lymphoma Phase II study (2021). www.tessacell.com/2021/04/30/tessa-therapeutics-announces-enrollment-of-12-patient-pilot-cohort-in-its-relapsed-or-refractory-hodgkin-lymphoma-phase-2-study/
- Organicell Regenerative Medicine . Organicell announces FDA approval of IND application for the use of Zofin™ in the treatment of osteoarthritis (2021). https://organicell.com/2021/04/21/organicell-announces-fda-approval-of-ind-application-for-the-use-of-zofin-in-the-treatment-of-osteoarthritis/
- Orthofix Medical . Orthofix announces FDA clearance and initial patient implant of the company’s first 3D-printed titanium cervical spacer system with Nanovate Technology (2021). https://ir.orthofix.com/press-releases/news-details/2021/Orthofix-Announces-FDA-Clearance-and-Initial-Patient-Implant-of-the-Companys-First-3D-Printed-Titanium-Cervical-Spacer-System-with-Nanovate-Technology/default.aspx
- Orthofix Medical . Orthofix announces FDA clearance and first patient implant of the 3D-printed FORZA titanium TLIF Spacer System with Nanovate Technology (2021). https://ir.orthofix.com/press-releases/news-details/2021/Orthofix-Announces-FDA-Clearance-and-First-Patient-Implant-of-the-3D-Printed-FORZA-Titanium-TLIF-Spacer-System-with-Nanovate-Technology/default.aspx
- Vertex Pharmaceuticals . Vertex and CRISPR therapeutics announce priority medicines (PRIME) designation granted by the European Medicines Agency to CTX001™ for transfusion-dependent beta thalassemia (2021). https://news.vrtx.com/press-release/vertex-and-crispr-therapeutics-announce-priority-medicines-prime-designation-granted
- Arcellx . Arcellx closes $115 million series C financing to advance its pipeline of adaptive and controllable cell therapies (2021). https://arcellx.com/arcellx-closes-115-million-series-c-financing-to-advance-its-pipeline-of-adaptive-and-controllable-cell-therapies/
- Arcellx . Arcellx announces FDA clearance of IND application for ACLX-001, a controllable cell therapy utilizing the company’s ARC-SparX platform, for the treatment of multiple myeloma (2021). https://arcellx.com/arcellx-announces-fda-clearance-of-ind-application-for-aclx-001-a-controllable-cell-therapy-utilizing-the-companys-arc-sparx-platform-for-the-treatment-of-multiple-myeloma/
- Janux Therapeutics . Janux Therapeutics closes $125 million Series B financing to advance next generation T cell engager immunotherapies into clinical trials (2021). www.januxrx.com/janux-therapeutics-closes-125-million-series-b-financing-to-advance-next-generation-t-cell-engager-immunotherapies-into-clinical-trials/
- Kadimastem . Kadimastem raises NIS 22.3 million ($6.8 million) (2021). www.kadimastem.com/post/kadimastem-raises-nis-22-3-million-6-8-million
- Polyneuron Pharmaceuticals . Polyneuron and University of Basel awarded grant of CHF 1.2 M to advance novel treatments to support ABO-incompatible transplants (2021). https://polyneuron.com/wp-content/uploads/2021/04/210414-Polyneuron-Innosuisse-Grant.pdf